Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study

The present study investigated outcomes of infliximab (IFX) treatment among 8 Japanese patients with various types of cancer (4 with malignant melanoma, 3 with lung cancer and 1 with renal cancer) who developed severe steroid-resistant immune-related adverse events (irAEs) in association with immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadokawa, Yukio, Takagi, Mari, Yoshida, Tomoe, Tatsumi, Akitoshi, Fujita, Keiko, Inoue, Takako, Ohe, Shuichi, Nakai, Yasutomo, Yamamoto, Sachiko, Otsuka, Tomoyuki, Ishihara, Ryu, Isei, Taiki, Kumagai, Toru, Nishimura, Kazuo, Imamura, Fumio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890436/
https://www.ncbi.nlm.nih.gov/pubmed/33680456
http://dx.doi.org/10.3892/mco.2021.2227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890436/
https://www.ncbi.nlm.nih.gov/pubmed/33680456
http://dx.doi.org/10.3892/mco.2021.2227

Ejemplares similares